{"id":54718,"date":"2023-03-10T13:05:23","date_gmt":"2023-03-10T12:05:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/"},"modified":"2023-03-10T13:05:23","modified_gmt":"2023-03-10T12:05:23","slug":"olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/","title":{"rendered":"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nThe Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) has awarded a grant from their Therapeutics Pipeline Program to support preclinical research evaluating Olatec Therapeutics\u2019 lead compound, dapansutrile, in Parkinson\u2019s disease (PD)\n<\/li>\n<li>\nUnder this grant Olatec, in collaboration with Dr. Nadia Stefanova (Medical University of Innsbruck), will be studying dapansutrile in both wildtype and transgenic mice with \u03b1-synuclein inclusion pathology to assess dapansutrile\u2019s effect on motor symptoms and lowering neuroinflammation and plaque formation\n<\/li>\n<li>\nPD motor clinical symptoms are thought to arise after substantial loss of the dopamine-producing cells of the substantia nigra; currently, there are no therapeutics that can alter PD progression\n<\/li>\n<li>\nDapansutrile has previously been found to protect substantia nigra cells in another PD mouse model\n<\/li>\n<\/ul>\n<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/COVID19?src=hash\" target=\"_blank\" rel=\"noopener\">#COVID19<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.olatec.com%2F&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=Olatec+Therapeutics+LLC&amp;index=1&amp;md5=c65fb3c8796db1500012aeb9d30da540\" rel=\"nofollow noopener\" shape=\"rect\">Olatec Therapeutics LLC<\/a> (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) awarded a research grant to evaluate Olatec\u2019s lead molecule, dapansutrile, in preclinical Parkinson\u2019s disease (PD) progression models. These studies are being initiated in collaboration with researchers at the Medical University of Innsbruck in Austria. The studies will assess dapansutrile\u2019s potential effect as an anti-neuroinflammatory agent, and its pharmacokinetics to confirm validated target engagement in certain transgenic and propagation mouse models. The aim of this collaboration is to accelerate the development of a potential therapeutic intervention that may prevent or mitigate the development of PD\u2019s motor and non-motor symptoms.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230310005096\/en\/1087939\/4\/01-09-15-Olatec.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230310005096\/en\/1087939\/21\/01-09-15-Olatec.jpg\"><\/a><\/p>\n<p>\nPD is a complex neurodegenerative disease marked by motor symptoms and in some cases dementia. Loss of neurons in areas that produce dopamine, particularly the substantia nigra, leads to decline in motor performance. Mounting scientific literature suggests a neuroinflammatory process related to aggregation of \u03b1-synuclein protein as a potential driver of these changes. A protein found abundantly in the brain, \u03b1-synuclein, typically functions in facilitating communications between neurons; however, misfolded \u03b1-synuclein can aggregate into intracellular inclusions (Lewy bodies). Age-related accumulation of tangled \u03b1-synuclein protein may initiate or run in parallel to an inflammatory cascade resulting in neuron death. As such, significantly, down regulating neuroinflammatory processes may prevent or slow formation of \u03b1\u2011synuclein aggregation.\n<\/p>\n<p>\nWhen asked about the MJFF grant, Charles Dinarello MD, Olatec SAB Chair, said: \u201cThe data we have generated using a standard mouse model of Parkinson&#8217;s disease allow us to advance our findings with the models to be used by Dr. Stefanova. Specifically, our current data reveal that dapansutrile\u2019s reduction in brain levels of pro-inflammatory cytokines, IL-1\u03b2 and IL\u201118, results in significant improved locomotion and lower brain levels of the pathologic \u03b1-synuclein. We are very pleased to receive this grant from the MJFF and are hopeful the findings will advance us into a clinical trial with dapansutrile in Parkinson&#8217;s disease.\u201d\n<\/p>\n<p>\nThe study, funded by the MJFF grant, will investigate treatment with oral dapansutrile in both an \u03b1\u2011synuclein propagation model in wildtype mice and a transgenic mouse model with upregulated production of full-length human \u03b1-synuclein leading to progressive motor deficits. The aim of the study will be to quantify how oral dapansutrile might protect neurons, reduce \u03b1-synuclein aggregation and neuroinflammation, and prevent motor deficits. Additionally, the study will evaluate tolerability and pharmacokinetics in the murine system.\n<\/p>\n<p>\nNadia Stefanova MD PhD, the lead investigator on this study, is a professor in the Department of Neurology, Medical University of Innsbruck. Dr. Stefanova is a leader in the field of \u03b1-synucleinopathies, which are neurodegenerative diseases characterized by the accumulation of misfolded \u03b1-synuclein in brain tissue, including PD, Lewy Body Dementia, and Multiple System Atrophy. Dr. Stefanova\u2019s research focus includes the development of experimental mouse models for therapeutic development as well as the significance of neuroinflammatory responses in disease mechanisms. Commenting on the MJFF grant, Dr. Stefanova said: \u201cWe are looking forward to the preclinical investigation of dapansutrile in our \u03b1-synuleinopathy models to further advance PD science and investigate the drug\u2019s potential mechanism of action in treating this disease. I am also thrilled to launch our collaboration with Olatec and the lab of Charles Dinarello with the funding support of MJFF, and to work on the preclinical evaluation of dapansutrile for the treatment of PD and related disorders.\u201d\n<\/p>\n<p>\nOlatec\u2019s Founder and CEO Damaris Skouras commented: \u201cOlatec is very pleased to be awarded this grant, and to be collaborating with Dr. Stefanova on this important research evaluating dapansutrile in the potential treatment of this debilitating disease with unmet medical need.\u201d\n<\/p>\n<p>\n<b>++++++++++++++++++++++++++++++++++++++<\/b>\n<\/p>\n<p>\n<b>About Parkinson\u2019s disease<\/b>\n<\/p>\n<p>\nNearly one million Americans are living with PD, and close to 90,000 will be diagnosed this year. Currently, there are no therapeutics that can alter PD disease progression. Patients initially present with complaints of changes in sleep, movement, and speech; worsening physical symptoms are later met with the development of cognitive decline. Medications such as levodopa are palliative, reducing symptom burden but unable to alter disease progression.\n<\/p>\n<p>\n<b>About Dapansutrile<\/b>\n<\/p>\n<p>\nDapansutrile (lab code: OLT1177<sup>\u00ae<\/sup>) is an investigational small molecule, new chemical entity that specifically binds to and blocks NLRP3 (nucleotide-binding and oligomerization domain [NOD]\u2011, leucine rich repeat-, pyrin domain-containing 3), the sensor molecule integral in the formation of the NLRP3 inflammasome. Inflammasomes are multiprotein complexes involved in intracellular surveillance of danger signals that trigger an intense inflammatory response, via generation of bioactive IL-1\u03b2 and IL-18 through caspase-1 activation. Dapansutrile has been shown to prevent the formation of the NLRP3 inflammasome, which in turn inhibits the production of IL-1\u03b2 and IL\u201118. NLRP3 is one of the most characterized inflammasome sensors due to its involvement in a wide range of disorders, including sterile inflammation, infections, and rare genetic autoimmune syndromes. Dapansutrile has been well tolerated and shown to improve clinical outcomes in patients with acute gout flare (see <span class=\"bwuline\"><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanrhe%2Farticle%2FPIIS2665-9913%252820%252930065-5%2Ffulltext&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=The+Lancet+Rheumatology&amp;index=2&amp;md5=454d05c30b53a1632d55af05e11d86fc\" rel=\"nofollow noopener\" shape=\"rect\">The Lancet Rheumatology<\/a><\/i><\/span>) and heart failure (see <span class=\"bwuline\"><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.lww.com%2Fcardiovascularpharm%2FAbstract%2F9000%2FA_Phase_IB%2C_Randomized%2C_Double_Blinded%2C_Dose.98314.aspx&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=Journal+of+Cardiovascular+Pharmacology&amp;index=3&amp;md5=9fb19d4d897acb95acb6146d201b5a01\" rel=\"nofollow noopener\" shape=\"rect\">Journal of Cardiovascular Pharmacology<\/a><\/i><\/span>). Dapansutrile has also been observed to have anti-inflammatory properties and other promising activity in a broad spectrum of over 20 preclinical animal models including arthritis, asthma, acute myocardial infarction (AMI), heart failure, contact dermatitis, multiple sclerosis, melanoma, pancreatic and breast cancers, spinal cord injury (SCI), Parkinson\u2019s and Alzheimer\u2019s disease. For a complete list of Olatec\u2019s original publications on dapansutrile in various preclinical and clinical disease areas, please refer to Olatec\u2019s publication page, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.olatec.com%2Folatec-publications.html&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=3f9750bb951d847678babff0934bf831\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a>.\n<\/p>\n<p>\n<b>About Dapansutrile\u2019s Preclinical CNS Research<\/b>\n<\/p>\n<p>\nDapansutrile is being studied in multiple models of the central nervous system and neuroinflammation, including: Alzheimer\u2019s disease (AD), spinal cord injury (SCI), multiple sclerosis (MS), and Parkinson\u2019s disease (PD). Data to date from these different programs have been or are being published as follows: in the AD studies, data revealed that oral dosing with dapansutrile inhibits pathophysiological inflammatory processes, recovers significant cognitive losses and prevents neuroinflammation in the brains of transgenic mice induced with AD (see publication in <span class=\"bwuline\"><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pnas.org%2Fcontent%2Fearly%2F2020%2F11%2F25%2F2009680117&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=PNAS%29&amp;index=5&amp;md5=805523148f81d9ecd8e429a5b79e5541\" rel=\"nofollow noopener\" shape=\"rect\">PNAS)<\/a><\/i><\/span>. In models of MS, dapansutrile exerted anti-inflammatory and protective effects on functional and histological outcomes in experimental autoimmune encephalomyelitis mice, when given prophylactically (see publication in <span class=\"bwuline\"><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2019.02578%2Ffull&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=Frontier+in+Immunology&amp;index=6&amp;md5=5729996b105f20da20741308c9cbd24b\" rel=\"nofollow noopener\" shape=\"rect\">Frontier in Immunology<\/a><\/i><\/span><i>)<\/i>. In MPTP models of PD, dapansutrile showed reduced <span>\u03b1<\/span>-synuclein aggregation, preserved dopaminergic neuron survival and reduced IL\u201118 levels. In spinal cord injury (SCI) models, dapansutrile protected against neurological deficits and histological evidence of damage (see publication in <span class=\"bwuline\"><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34624330%2F&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=Experimental+Neurology&amp;index=7&amp;md5=22576798d378856cab4434a5b9f034ad\" rel=\"nofollow noopener\" shape=\"rect\">Experimental Neurology<\/a><\/i><\/span><i>)<\/i>.\n<\/p>\n<p>\n<b>About Olatec Therapeutics LLC<\/b>\n<\/p>\n<p>\nOlatec is a privately held, Phase 2\/3 clinical-stage biopharmaceutical company developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases known to be mediated by IL-1 (see list of clinical trials to-date, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.olatec.com%2Fpatients.html&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=here&amp;index=8&amp;md5=8bcc9e7d6aca370a258241c4e2d44464\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a>). In addition to the lead compound, dapansutrile, Olatec\u2019s platform of proprietary compounds includes approximately 60 analogues (OLT Analogues) being screened as viable drug candidates. A portfolio of intellectual property registrations protecting Olatec\u2019s compounds consists of over 130 patents granted, covering dapansutrile and OLT Analogues. Olatec\u2019s drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology and has been involved in the discovery and development of first-line inflammation treatments in the market today. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.olatec.com&amp;esheet=53359610&amp;newsitemid=20230310005096&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.olatec.com&amp;index=9&amp;md5=ebfc9a2fc1033a86e08d74c684ffdfa2\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.olatec.com<\/a>\n<\/p>\n<p>\n<b><i>Disclaimer &amp; Forward-looking Statement<\/i><\/b>\n<\/p>\n<p>\n<i>This press release is not an offer to sell and is not soliciting an offer to buy any equity interests in the Company. The information contained herein is being provided for information purposes only. The Company makes no express or implied representation or warranty as to the completeness of this information. Any forward-looking statements contained in this release are based on assumptions made by Olatec at the time this Press Release was prepared. Any forward-looking statement contained in this Press Release is subject to known and unknown risks, uncertainties and other factors that may be materially different from those contemplated in such forward-looking statements. All information with respect to industry data has been obtained from sources believed to be reliable and current, but the accuracy thereof cannot be guaranteed by the Company. Olatec does not undertake any obligation to update or revise the forward-looking statements contained in this Press Release to reflect events or circumstances occurring after the date this Press Release was prepared, or to reflect the occurrence of unanticipated events.<\/i>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Olatec<br \/>\n<br \/><\/b>Damaris B. Skouras, Co-Founder and CEO, and<br \/>\n<br \/>Olatec Investor Relations &amp; Communications: <a target=\"_blank\" href=\"mailto:ir&#64;ol&#97;&#116;&#101;&#99;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x72;&#x40;&#x6f;&#x6c;&#97;&#116;&#101;&#99;&#46;co&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) has awarded a grant from their Therapeutics Pipeline Program to support preclinical research evaluating Olatec Therapeutics\u2019 lead compound, dapansutrile, in Parkinson\u2019s disease (PD) Under this grant Olatec, in collaboration with Dr. Nadia Stefanova (Medical University of Innsbruck), will be studying dapansutrile in both wildtype and transgenic &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54718","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) has awarded a grant from their Therapeutics Pipeline Program to support preclinical research evaluating Olatec Therapeutics\u2019 lead compound, dapansutrile, in Parkinson\u2019s disease (PD) Under this grant Olatec, in collaboration with Dr. Nadia Stefanova (Medical University of Innsbruck), will be studying dapansutrile in both wildtype and transgenic ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-10T12:05:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230310005096\/en\/1087939\/21\/01-09-15-Olatec.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression\",\"datePublished\":\"2023-03-10T12:05:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/\"},\"wordCount\":1547,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230310005096\\\/en\\\/1087939\\\/21\\\/01-09-15-Olatec.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/\",\"name\":\"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230310005096\\\/en\\\/1087939\\\/21\\\/01-09-15-Olatec.jpg\",\"datePublished\":\"2023-03-10T12:05:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230310005096\\\/en\\\/1087939\\\/21\\\/01-09-15-Olatec.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230310005096\\\/en\\\/1087939\\\/21\\\/01-09-15-Olatec.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/","og_locale":"en_US","og_type":"article","og_title":"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression - Pharma Trend","og_description":"The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) has awarded a grant from their Therapeutics Pipeline Program to support preclinical research evaluating Olatec Therapeutics\u2019 lead compound, dapansutrile, in Parkinson\u2019s disease (PD) Under this grant Olatec, in collaboration with Dr. Nadia Stefanova (Medical University of Innsbruck), will be studying dapansutrile in both wildtype and transgenic ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-10T12:05:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230310005096\/en\/1087939\/21\/01-09-15-Olatec.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression","datePublished":"2023-03-10T12:05:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/"},"wordCount":1547,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230310005096\/en\/1087939\/21\/01-09-15-Olatec.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/","url":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/","name":"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230310005096\/en\/1087939\/21\/01-09-15-Olatec.jpg","datePublished":"2023-03-10T12:05:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230310005096\/en\/1087939\/21\/01-09-15-Olatec.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230310005096\/en\/1087939\/21\/01-09-15-Olatec.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/olatec-therapeutics-awarded-a-grant-from-the-michael-j-fox-foundation-in-collaboration-with-medical-university-of-innsbruck-to-evaluate-dapansutrile-in-animal-models-of-parkinsons-disease-pr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54718"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54718\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}